Masimo to Report Fourth Quarter and Full Year 2019 Financial Results after Market Close on Wednesday, February 19
13 February 2020 - 8:05AM
Business Wire
Conference call and webcast to begin at 1:30
p.m. PT (4:30 p.m. ET)
As previously announced on January 14, Masimo (NASDAQ: MASI)
will release fourth quarter and full year 2019 financial results
for the period ended December 28, 2019, after the market closes on
Wednesday, February 19, 2020. The conference call to review the
results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be
hosted by Joe Kiani, Chairman and Chief Executive Officer, and
Micah Young, Executive Vice President and Chief Financial
Officer.
A live webcast of the conference call will be available online
from the investor relations page of the Company’s corporate website
at www.masimo.com. The dial-in numbers are (833) 227-5837 for
domestic callers and +1 (825) 312-2251 for international callers.
The reservation code for both dial-in numbers is 2862927. After the
live webcast, the call will be available on Masimo’s website
through March 19, 2020. In addition, a telephonic replay of the
call will be available through March 4, 2020. The replay dial-in
numbers are (800) 585-8367 for domestic callers and +1 (416)
621-4642 for international callers. Please use reservation code
2862927.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.4-6 Masimo SET® is estimated to be used on
more than 100 million patients in leading hospitals and other
healthcare settings around the world,7 and is the primary pulse
oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S.
News and World Report Best Hospitals Honor Roll.8 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET™
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97™. Masimo hospital
automation and connectivity solutions are centered around the Iris®
platform, and include Iris Gateway™, Patient SafetyNet, Replica™,
Halo ION™, UniView™, and Doctella™. Additional information about
Masimo and its products may be found at www.masimo.com. Published
clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer AH et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for
General Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Masimo, SET, Signal Extraction Technology, Improving Patient
Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring
to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet,
PVI are trademarks or registered trademarks of Masimo.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200212005330/en/
Investor Contact: Eli Kammerman (858) 859-7001
ekammerman@masimo.com Media Contact: Irene Paigah (949) 297-7077
irenep@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2024 to May 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From May 2023 to May 2024